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Forward IMRTAbstract Purpose: Our aim was to investigate if, and to what degree, improvements of IMRT
treatment plans generated by forward planning can be achieved with an inverse planning strategy
for treatments of head and neck cancer.
Methods: Between June 2007 and April 2008, 19 patients with head-and-neck cancers were treated
at KAAH and Oncology Center Jeddah, using forward planning intensity modulated radiation
therapy (FP-IMRT). They received thirty fractions over six weeks, to simultaneously deliver
66 Gy to the gross tumor (CTV1), 60 Gy to the soft tissue and nodes adjacent to the previous vol-
ume (CTV2), and 54 Gy to elective nodes (CTV3). These are biologically equivalent to 70, 60, and
50 Gy, if given 2 Gy per fraction.
These were retrospectively re-planned with an inverse planning algorithm (IP-IMRT). The main
objective of the optimization process was sparing of the parotid glands, spinal cord, and brainstem
beside adequate treatment of the planning target volume.
Results: Having 95% and 98% of CTV1 to receive at least 95% and 90% of prescribed dose
respectively was fulﬁlled in all cases in both groups with higher ﬁgures in group B (IP-IMRT) than
in group A (FR-IMRT), more obvious in CTV2 and CTV3. The average maximum dose to the
120 A. Nasr, A. Habashspinal cord was 45.1 Gy in group A, and 41.6 Gy in group B. The mean dose of both parotid glands
was kept below 26 Gy in four patients in group A, but in all cases in group B.
Conclusion: IP-IMRT selectively spared critical organs to greater degree with better target cover-
age and should be considered the standard of treatment in head and neck tumors.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
External beam radiation therapy has long been a cornerstone
of therapy for early stage and loco regionally advanced head
and neck cancer. ‘Conventional radiotherapy’ involves the
delivery of fractionated radiation (commonly 2 Gy daily to
70 Gy) and is complicated by the close proximity of tumor
and normal tissue structures such as the spinal cord, brain
stem, parotid glands and the optic pathway. In conventional
radiotherapy, masking techniques, routine laser alignment,
and daily set-up, variations of 3–6 mm are common. To allow
for these variations, and for uncertainties in tumor deﬁnition,
generous safety margins are used. While this approach helps to
ensure irradiation of all malignant tissues, it also subjects
healthy tissues to full dose radiation exposure and the recog-
nized side effects of treatment. Radiation mucositis with asso-
ciated pain is experienced by virtually all patients and can last
for 3–8 weeks following treatment [1].
Chronic radiation toxicities, including mucosal ﬁbrosis and
atrophy, xerostomia, dental decay, soft tissue necrosis, osteone-
crosis and taste disturbances (dysgeusia, ageusia), can occur in
many patients. These effects can lead to a lifetime risk of oral
sequelae with profound effects on patient quality of life [2].
One of the more recent adaptations of radiotherapy
involves the use of intensity-modulated radiation therapy
(IMRT) [3]. In IMRT, multiple shaped radiation beams are
modulated to produce highly conformal dose distributions.
This approach enables the delivery of increased doses to tumor
tissue while limiting the dose delivered to deﬁned normal struc-
tures such as the salivary glands, auditory and optic apparatus,
spinal cord and larynx [4].
IMRT can be divided into two broad categories, forward
planning (FP-IMRT) and inverse planning (IP-IMRT). In for-
ward planning, the planning dosimeters or physicist selects the
number, energy, weighting, and angle of beams. The computer
then calculates the dose distribution and generates beam’s-eye
views, along with dose–volume histograms. The plan is opti-
mized by manual iteration. This is in contrast to inverse plan-
ning, where one begins by deﬁning the desired dose to the
target and the normal tissues, and the computer with its opti-
mization program will go through multiple automatic itera-
tions seeking to ﬁnd the best beam parameters that will yield
the desired dose distribution [5].
Previous comparisons between conventional and intensity-
modulated treatment planning have demonstrated the poten-
tial to improve dose distributions with intensity-modulated
radiotherapy (IMRT) for several tumor sites together with
decreasing both acute and late reactions [6,7].
Many studies demonstrated the potential of inverse
planning to improve intensity-modulated treatment plans for
head and neck cases compared to forward planning while
retaining clinical utility in terms of treatment time and quality
assurance [8–10].The aim of this work is to investigate if, and to what degree,
improvements of IMRT treatment plans generated by forward
planning can be achieved with an inverse planning strategy.
For this aim, we compared a clinically applied forward plan-
ning procedure with an inverse planning technique for a set
of patients suffering from head and neck tumors.
Materials and methods
This is a dosimetric descriptive study which was done at the
King Abdul Aziz Hospital and Oncology Center, Jeddah to
compare the dosimetric ﬁgures of FP and IP IMRT techniques
in head and neck cancer cases.
Materials. The materials used in this study are the plans of
nineteen patients with primary head- and-neck cancers who
were treated between June 2007 and April 2008 by FP-IMRT.
These patients were studied by Hussein Omar and Ahmad
Habash, [11]. Patients who were previously untreated, 18 years
or older, with histologically conﬁrmed non metastatic squa-
mous cell carcinoma of the nasopharynx, oropharynx, hypo-
pharynx, larynx, tonsil or oral cavity were eligible for the
study. (Characteristics are shown in Table 1). The aim of this
work is to compare all the ﬁgures obtained from these plans
with the corresponding ones if the method used was IP-IMRT
instead of FP-IMRT.
In order to achieve our aim we used the same targets and
sensitive structures delineated for these patients and re-
planned them using the inverse technique. Same fractionation
scheme and same approval plan were used.
Simulation and immobilization were mentioned in detail by
Hussein Omar, Ahmad Habash [11].
CT scans in serial 3-mm axial slices were obtained for treat-
ment planning. CT images were acquired at least 6 cm beyond
the cranial and caudal limits of the largest treatment target.
Target and sensitive structure delineation was done using the
CMS planning system. Clinical target volume1 (CTV1), clini-
cal target volume 2 (CTV2), clinical target volume 3 (CTV3),
and the normal critical tissues, all were outlined on each axial
CT slice. The CTV1 was deﬁned as the gross tumor (primary
and enlarged nodes) with margins based on radiological and
clinical justiﬁcation [12]. The CTV2 is deﬁned as soft tissue
and nodal regions adjacent to CTV1 while CTV3 is deﬁned
as elective nodal regions as well as margins to account for
patient motion and setup errors. The normal critical structures
included and evaluated were the brainstem, spinal cord, and
parotid glands.
Fractionation scheme. The RTOG H-0022 protocol was fol-
lowed [13]. Thirty daily fractions over six weeks were used to
simultaneously deliver 66 Gy (2.2 Gy/fraction) to CTV1,
60 Gy (2 Gy/fraction) to CTV2, and 54 Gy (1.8 Gy/fraction)
to CTV3. These are biologically equivalent to 70, 60, and
50 Gy, respectively, if given in 2 Gy per fraction. The maxi-
mum dose to the brainstem and spinal cord are maintained
Table 1 Patient’s characteristics.
Characteristics No. of Patients %
Sex
Male 13 68
Female 6 32
Age (years)
Median 49 years
Range 42–63 years
Primary site of the tumor
Nasopharynx 9 48
Hypopharynx 2 10.5
Larynx 2 10.5
Oropharynx 1 5
Tonsillar fossa 1 5
Floor of mouth 2 10.5
Base of tongue 2 10.5
T-stage
T1 1 5
T2 3 16
T3 12 63
T4 3 16
N-stage
NO 2 11
N1 7 37
N2 9 47
N3 1 5
Pathology
Diﬀerentiated 9 47
Undiﬀerentiated 10 53
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is maintained below 26 Gy, or at least 50% of one of the par-
otids is maintained below 30 Gy.
Beam conﬁguration for FP-IMRT treatment planning
(group A): seven beams were used with beam angle arrange-
ments, including an anterior, 2 laterals, 2 anterior oblique,
and 2 posterior oblique beams with a total of 22 beam shapes
formed by multileaf collimators (MLC). Five of the 7 beam
directions contained 20 segments (four segments for each) with
equal weighting however the 2 lateral beams are not segmented.
A single isocenter was used for all beams. The segments used in
a given angle are tailored to maximize the coverage of the target
while minimizing the normal tissue exposure. More details are
mentioned in Hussein Omar, and Ahmad Habash [11].
Once the typical beam arrangements were set, numerous
adjustments and ﬁne tuning were done to increase dose homo-
geneity and to decrease the dose delivered to the normal tis-
sues. The shape of each MLC was carefully designed along
with the associated weights. Manual iterations were done to
optimize the plan.
For IP-IMRT (group B) ﬁrst, the planner may create help
structures which guide the optimizer to achieve the acceptance
criteria faster. Using the same isocenter as in group A and 7
co-planner ﬁelds with equal gantry angle separation (51)
the constrain (s) of each target, critical structure, and help
structure were fed to the optimizer. Start of optimization,
review of optimization result using DVH, change of constrain
and rerun of optimization were done until the acceptance
criteria was acheived. Now it is ready to make the MLC
segmentation from an optimum ﬂuency map. After ﬁnal calcu-lations the acceptance criteria of targets and critical structures
were reviewed using DVH, change of constrain and rerun of opti-
mization were done if needed to achieve the acceptance criteria.
Plan approval. The aims of the treatment were to achieve
90% of the prescribed dose to at least 98% of the volumes of
CTV1, CTV2 and CTV3 and a dose of 95% in at least 95%
of CTV1, CTV2 and CTV3. The maximum dose of the spinal
cord is to be limited to 50 Gy. Furthermore, the mean dose
of either parotid gland should not exceed 26 Gy or at least
50% of one of the parotids is to be maintained below 30 Gy.
Treatment delivery and quality assurance
For IP-IMRT
Treatment planning: First, all ﬁelds were manually recalculated
toverify the calculatedMUfromthe planning system.At the start
of radiotherapy, 22 ﬁlms were taken to verify the treatment ﬁelds.
Once all portal images matched exactly with the digitally recon-
structed radiographs, weekly orthogonal portal ﬁlms were taken
to verify the treatment isocenter. Necessary shifts in the isocenter
were made during treatment as the discretion of the treating
physician. For a selected plan, a phantom QA plan was created
with the beams gantry angle normalized to 0 with the same
intensity distributions as used in the treatment plan. The dose
distribution was recalculated in the phantom based on its
geometry. The phantomconsisted of a stack of square solid water
slabs with the presence of ﬁve positions for ionization chambers.
The dosimetric accuracy of this technique was veriﬁed with a
phantom QA plan and measured with ﬁve ionization chambers.
All patients were treated with 6 MV photon beams from
Siemens (Oncor Impression) accelerator with autosequencing
of all treatment segments.
For IP-IMRT
First, the plan is exported to the treatment machine and all MU
and gantry angle of the ﬁelds checked. Each ﬁeld was treated
using port-during option to see the overall shape of each treat-
ment ﬁeld and compare it to its shape from the planning system.
For each plan, a phantom QA plan was created similar to
FP-IMRT. The dosimetric accuracy of this technique was ver-
iﬁed with a phantom QA plan and measured with ﬁve ioniza-
tion chambers.
Results
The patient characteristics, primary site distribution, and pri-
mary and nodal staging are shown in Table 1.
Plan evaluation of target volume coverage and normal tis-
sue sparing are shown in Table 2. Tables 2a (ﬁgures of patients
1–9) and 2b (ﬁgures of patients 10–19) present the percentage
of volume of CTV1, CTV2 and CTV3 received at 95% and
90% of the prescribed dose, together with the maximum dose,
the dose to ten percent of the spinal cord, dose to brain stem,
and the mean dose to the right and left parotid glands.
1. The aim of having at least 95% and 98% of CTV1 to
receive at least 95% and 90% of the prescribed dose respec-
tively was fulﬁlled in all cases in both groups with the fact
that in all cases coverage was higher in group B (IP-IMRT)
than in group A (FP-IMRT).
Table 2 The results of both the FP-IMRT planning technique and the IN-IMRT planning technique for 19 patients.
Table 2a (ﬁgures of patients 1–9)
Patients 1 2 3 4 5 6 7 8 9
%Volume of CTV1receiving 95% of the dose 95
96*
95
97*
100
100*
96
98*
99
99*
95
97*
98
99*
97
98*
97
99*
90% of the dose 99
100*
98
100*
100
100*
100
100*
100
100*
98
100*
99
100*
100
100*
100
100*
%Volume of CTV2 receiving 95% of the dose 95
98*
91
96*
95
98*
95
98*
96
97*
80
93*
95
97*
96
99*
96
98*
90% of the dose 97
100*
96
99*
99
100*
98
100*
99
100*
95
100*
98
100*
98
100*
99
100*
%Volume of CTV3 receiving 95% of the dose 87
97*
81
94*
90
98*
89
98*
88
97*
82
97*
99
100*
92
98*
95
99*
90% of the dose 90
100*
89
99*
97
100*
97
100*
95
100*
95
100*
100
100*
97
100*
98
100*
Maximum dose (Gy) of the spinal cord 48
45*
39
37*
50
46*
49
44*
47
42*
48
43*
48
42*
46
41*
45
42*
Dose to10% of spinal cord volume 44
38*
30
32*
47
39*
41
33*
42
36*
40
37*
42
36*
42
35*
43
33*
Maximum dose (Gy) of the Brainstem 49
41*
53
45*
51
44*
48
39*
50
45*
49
43*
48
41*
54
49*
47
41*
Mean dose (Gy) of the left parotid gland 23
20*
40
30*
38
29*
25
21*
38
26*
24
20*
24
19*
36
26*
25
21*
Mean dose (Gy) of the right parotid gland 26
21*
21
18*
21
17*
22
19*
24
18*
42
29*
23
18*
24
20*
34
29*
Globule maximum 107
113*
108
113*
107
112*
106
111*
107
110*
109
114*
108
111*
107
112*
107
111*
Table 2b (ﬁgures of patients 10–19)
Patients 10 11 12 13 14 15 16 17 18 19
%Volume of CTV1 receiving 95% of the dose 95
97*
97
99*
100
100*
95
97*
97
99*
96
100*
95
97*
97
100*
95
99*
97
100*
90% of the dose 98
100*
99
100*
100
100*
99
100*
98
100*
99
100*
99
100*
98
100*
98
100*
100
100*
%Volume of CTV2 receiving 95% of the dose 96
*98
95
97*
96
99*
95
96*
80
94*
90
96*
95
97*
95
100*
88
97*
95
99*
90% of the dose 98
100*
99
100*
98
100*
99
100*
96
100*
92
100*
98
100*
98
100*
94
99*
98
100*
%Volume of CTV3 receiving 95% of the dose 85
91*
93
98*
95
99*
81
94*
82
95*
88
96*
95
99*
85
98*
86
96*
85
94*
90% of the dose 95
100*
97
100*
98
100*
88
97*
85
98*
90
99*
97
100*
97
100*
97
100*
93
100*
Maximum dose (Gy) of the spinal cord 42
39*
43
40*
45
42*
42
41*
39
38*
46
42*
43
39*
46
41*
44
43*
48
45*
Dose to10% of spinal cord volume 38
32*
39
31*
40
32*
38
33*
33
30*
43
31*
37
29*
35
28*
34
29*
40
39*
Maximum dose (Gy) of the Brainstem 51
42*
53
49*
54
49*
53
47*
54
50*
48
41*
47
42*
47
43*
51
48*
47
40*
Mean dose (Gy) of the left parotid gland 22
18*
26
21*
42
29*
26
19*
39
29*
29
21*
21
18*
23
21*
28
26*
21
19*
Mean dose (Gy) of the right parotid gland 35
30*
28
25*
23
21*
24
22*
22
19*
21
18*
43
32*
35
28*
21
20*
29
25*
Globule maximum 108
111*
109
112*
107
113*
107
114*
107
112*
109
112*
109
110*
106
114*
109
112*
106
109*
* Figures obtained from IN-IMRT plan
122 A. Nasr, A. Habash2. The criterion of having at least 95% and 98% of CTV2 to
receive at least 95% and 90% of the prescribed dose was
not achieved in ﬁve and six patients of group A respectively
with an average of 92.8% of the volume receiving 95% of
the dose and 97.3% of the volume receiving 90% of the
dose. While in group B the ﬁrst goal was not achieved inonly two cases in which 95% of the dose covered 93% of
CTV2 volume (which was only 80% of the volume in G
A of the same case) and in the other case the ﬁgure was
94% vs. 80% for the same case in group A. On the other
hand the second goal of having at least 98% of the volume
to be covered with at least 90%,was fulﬁlled in all cases in
Comparison of different IMRT techniques in head and neck cancer 123group B in comparison to 13 patients in group A. In case to
case comparisons the coverage was higher in all cases of
group B than group A.
The percentage of CTV3 that received a 95% dose had a
wide range (81–99%) with an average of 88.3% and the per-
centage that received 90% of the dose ranged from 85% to
100% with an average of 94.5% in group A, while in our group
although coverage of 95% of the dose was not achieved in 4
cases but the coverage in these cases was 94% in 3 of them
(vs. 81%, 81% and 85% in Group A) and 91% in the 4th
one (vs. 85% in group A). Regarding the volume of CTV3 cov-
ered by 90% the criteria was fulﬁlled in all cases except in one
case only in which the ﬁgure was 97% (vs. 88% in Group A)
again a case to case comparison and the coverage was higher
in all cases of group B than group A.
In groupA the maximum dose to the spinal cord ranged from
39 to 50 Gy (with average of 45.1 Gy).On the hand themaximum
dose to spinal cord was lower than the corresponding one in
group B in all cases with an average of 41.6 Gy. The dose to
10% of the spinal cord volume ranged from 30 to 47 Gy (with
averageof 39.3 Gy) in groupAwhile all the corresponding ﬁgures
were lower in group B with an average of 33.5 Gy. On the other
hand the dose to the brain stem was not more than 54 Gy in all
cases in both groups ranging in group A from 47 to 54 with an
average of 45.2 while the corresponding ﬁgures in group B were
ranging from 39 to 49 with an average of 35.2 Gy.
Regarding the mean dose of both parotid glands, in group
A, it was kept below 26 Gy in four patients, and the other ﬁf-
teen patients had at least one parotid gland below 26 Gy.
Among group B patients, we succeeded to keep the mean dose
of both parotid glands below 26 Gy in all patients.Discussion
The use of intensity-modulated radiotherapy (IMRT) is now
widely advocated for the treatment of head-and-neck cancers,
to increase the therapeutic ratio of radiotherapy used as the
sole modality of treatment or in combination with chemother-
apy [7,14].
The fractionation scheme is somewhat unique to IMRT
treatments, in which each of the target regions receives differ-
ent doses per fraction. Such a treatment strategy has been
called a simultaneous integrated boost (SIB). By reducing the
overall treatment time biological beneﬁts are also expected
due to the fast proliferation rate characterizing head and neck
tumors. IMRT, forward or inversely optimized, was radiobio-
logically and dosimetrically signiﬁcantly superior to conven-
tional plans [15,16].
Clinical implementation of IMRT using forward planning
is relatively easy, because it is closely related to and considered
as a logical extension of the experience obtained with confor-
mal radiotherapy. Manual deﬁnition of the segments leads to
intuitive choices of segment shapes based on the beam’s eye
view option of the planning system. Inverse planning is far less
related to conventional radiotherapy because the segment
shapes are not deﬁned manually and the number of segments
is usually considerably larger. However, there are complex
clinical situations, which require the use of many beam direc-
tions and segments. In these cases, inverse planning may be
the more efﬁcient strategy [17].Although IP-IMRT is an ideal treatment technique for
head-and-neck cancer patients especially for some complex
clinical situations, [18,19] this technology is not readily avail-
able in every radiotherapy clinic throughout the world due
to several factors, including economic and technical con-
straints. The longer daily treatment time associated with IP-
IMRT may also be a hindrance for a busy clinic trying to
accommodate all patients requesting IP-IMRT. Lastly, some
patients are simply not ideal candidates for IP-IMRT, because
of their inability to remain immobilized for a prolonged time
during the course of treatment [5]. However all studies com-
paring both forward and inverse planning were in favor of
using inverse IMRT.
In a similar study like ours Werner et al. [8], studied the
plans of ten patients who were treated with FP-IMRT. They
were retrospectively re-planned with an inverse planning algo-
rithm. The main objective of the optimization process was the
sparing of the parotid glands beside an adequate treatment of
the planning target volume (PTV). They found that inverse
planning strategies managed to improve the treatment plans
distinctly due to a better target coverage, a better sparing of
the parotid glands or both. A reduction of the mean dose by
3–11 Gy for at least one of the parotid glands could be
achieved for most of the patients. For three patients, inverse
planning allowed to spare a parotid gland that had to be sac-
riﬁced by forward planning. They even showed that this
improvement was achieved while retaining clinical utility in
terms of treatment time and quality assurance.
In our study, we can realize that better coverage of the tar-
get volume (CTV1, 2, and 3) was achieved in all cases with
inverse planning in comparison to the forward planning proce-
dure. This improvement was realized more regarding CTV2
and CTV3. The desired dose for CTV2 was achieved in 17
cases out of 19 in group B in comparison to 14 out of 19 in
group A. In group A the percentage of CTV3 that received a
95% dose had a wide range (81% to 99%) with an average
of 88.3% while the corresponding range in group B was from
91% to 100% with an average of 95.5%. and the percentage
that received 90% of the dose ranged from 85% to 100% with
an average of 94.5% in group A while the corresponding aver-
age in group B was 99.7%
In this study and that by Hussein Omar, and Ahmad
Habash, [11], the major aim of the parotid glands was to
achieve a mean dose below 26 Gy as proposed by Eisbruch
et al. [20]. In spite of the success in improving the coverage
at all target volumes in the group B (IP-IMRT), we also
succeeded to fulﬁll that aim in both glands in all the cases
in comparison to FP-IMRT in which sparing of both glands
was achieved in only four patients. The normal tissue com-
plication probability (NTCP) for the parotid glands pub-
lished by Eisbruch et al., and others [21] are continuous
and monotonously increasing functions of the mean dose
with a steep gradient between 20 and 30 Gy. Any signiﬁcant
reduction of the mean dose in this range may thus be of
clinical importance. This means that the expected clinical
improvement of the glands is very high with these doses par-
allel to improved dose distribution in the form of better
coverage.
Blanco et al. [22] investigated the factors that affect salivary
function after head-and-neck radiotherapy (RT), including
parotid gland dose–volume effects, potential compensation
by less-irradiated gland tissue and functional recovery over
124 A. Nasr, A. Habashtime. Radiotherapy (RT) was delivered using IP-intensity-
modulated RT (n= 45), forward-planning three-dimensional
conformal RT (n= 14), or three-dimensional conformal RT
with an intensity-modulated RT boost (n= 6). Whole salivary
ﬂow was measured before therapy and at 6 months (n= 61)
and 12 months (n= 31) after RT.
A signiﬁcant correlation was observed between the relative
quality-of-life scores and relative stimulated saliva values at
6 months after RT. The dose-volume factors were by far the
strongest correlates with stimulated saliva ﬂow, although other
factors showed modest signiﬁcance in multimetric models
(chemotherapy, gender, and Karnofsky performance status).
Salivary function, in each gland, appeared to be lost
exponentially at a rate of approximately 5%/1 Gy of mean
dose.
Poon et al. [9] compared dose-volume histograms of target
volumes and organs at risk in 57 patients with nasopharyngeal
carcinoma (NPC) with IP-IMRT (n= 31) or FP-IMRT
(n= 26). Treatment goals were to prescribe a minimum dose
of 66–70 Gy for gross tumor volume and 59.4 Gy for planning
target volume to greater than 95% of the volume. Multiple
selected end points were used to compare dose-volume histo-
grams of the targets. Dose–volume histograms of organs at
risk were evaluated with characteristic end points. Both plan-
ning methods provided excellent target coverage with no statis-
tically signiﬁcant differences found, although a trend was
suggested in favor of improved target coverage with IP IMRT
in patients with T3/T4 NPC (p= 0.10). IP IMRT statistically
decreased the dose to the parotid gland, tempro-mandibular
joint, brain stem, and spinal cord, whereas IP led to a dose
decrease to the middle/inner ear in only the T1/T2 subgroup.
They recommended that IP IMRT selectively spared these crit-
ical organs to a greater degree and should be considered the
standard of treatment in patients with NPC, particularly those
with T3/T4. The FP IMRT is an effective second option in cen-
ters with limited IP IMRT capacity. As a modiﬁcation of con-
formal techniques, the human/departmental resources to
incorporate FP-IMRT should be nominal.
Conclusion
Use of IP and FP IMRT can lead to good target coverage
while maintaining critical structures within tolerance. The IP
IMRT selectively spared these critical organs to a greater
degree together with better target coverage and should be con-
sidered the standard of treatment in patients with head and
neck tumors. The FP IMRT is an effective second option in
centers with limited IP IMRT capacity.Conﬂict of interest
The authors have no conﬂict of interest to declare.
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